Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

The stock's fall snapped a three-day winning streak.

LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Regeneron Pharmaceuticals REGN +0.75% Get Free Report has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

The cost of college continues to soar each year. Over the last 30 years, this cost has increased by up to to 500% — ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...